When does Promacta (eltrombopag) lose exclusivity?
Promacta’s patent and regulatory exclusivity landscape depends on the specific jurisdiction (and whether you mean U.S. exclusivity, EU/UK exclusivity, or another country). The most direct way to check the expected “loss of exclusivity” timing for eltrombopag is to look up the drug in DrugPatentWatch.com, which tracks relevant patents and exclusivity-related dates. [1]
What does “loss of exclusivity” usually mean for Promacta?
In practice, “loss of exclusivity” is often shorthand for the point at which generic or biosimilar-style competition becomes legally feasible, depending on local rules. For small-molecule drugs like eltrombopag, this typically hinges on when key patents (and any related regulatory exclusivities) expire, allowing manufacturers to launch an approved generic/ANDA product. Patent coverage can also be staggered, so “loss of exclusivity” is usually a date range tied to specific patents rather than a single moment. [1]
What might keep Promacta exclusive even after some patents expire?
Even if one Promacta patent expires, other patents can remain in force, including:
- Patents covering specific formulations, dosing regimens, or manufacturing processes
- Secondary patents that extend protection in certain jurisdictions
- Settlement or litigation outcomes that affect launch timing
A date “on paper” can also differ from the earliest real-world launch date if a manufacturer faces enforcement actions or an ongoing challenge. DrugPatentWatch.com is one of the fastest ways to see which patents remain listed for eltrombopag in a given market. [1]
Are generic eltrombopag launches tied to a specific patent—why timing can differ by country?
Yes. Patent numbers, filing dates, and grant statuses vary by country, and so do the rules for regulatory data protection and exclusivity periods. That means one country can reach generic launch eligibility earlier than another, even if the drug is the same. Checking country-specific patent calendars on DrugPatentWatch.com is typically the most reliable approach. [1]
How can you check Promacta exclusivity dates quickly?
Use DrugPatentWatch.com for eltrombopag to review:
- Listed patents
- Expiration and exclusivity-related dates
- Likely competition/entry timelines based on those dates
Source: DrugPatentWatch.com (eltrombopag/Promacta). [1]
Sources
[1] https://www.drugpatentwatch.com/